Thrombopoietin (TPO) is a liver-produced protein that drives megakaryocyte maturation. TPO regulates platelet production and can increase platelet and endothelial reactivity. We investigated the relationship between TPO and the occurrence of thrombocytopenia and thrombosis in patients with systemic lupus erythematosus (SLE).
Methods
We undertook a cohort study of SLE patients (n = 98) with clinical data collected simultaneously with sampling for TPO, inflammatory cytokines and autoantibody detection. TPO levels were measured by sandwich ELISA with patients with rheumatoid arthritis (RA) (n = 100) and controls (n = 79) as comparators. Disease associations were evaluated using non-parametric methods.
Results
TPO levels in SLE (median 8 pg/ml, mean 326, range 8992) were moderately increased compared with RA (median 8 pg/ml, mean 100, range 1659, p = 0.07) and controls (median 8, mean 94, range 2088, p = 0.1). Among SLE patients, TPO levels did not correlate with platelet count or levels of antiphospholipid antibodies. The prevalence of thrombocytopenic episodes, thrombotic events or active disease was not increased in patients with high TPO levels. TPO levels correlated with MIP-1α (Rs 0.56, p < 0.001), IL6 (Rs 0.26, p = 0.02) and IL4 (Rs 0.29, p = 0.01), and inversely correlated to C4 (Rs −0.23, p = 0.04). MIP-1α was the strongest independent predictor of increased TPO levels.
Conclusion
TPO levels are elevated in 20% of patients, but are not closely related to the occurrence of thrombocytopenia or thrombosis in SLE. MIP1-alpha is the main factor driving higher TPO levels among patients with SLE, likely through its inhibitory effect on megakaryocyte function.
LiJXiaYKuterDJ. Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: Binding, internalization, stability and pharmacokinetics. Br J Haematol1999; 106: 345–356.
2.
KuterDJ. Milestones in understanding platelet production: A historical overview. Br J Haematol2014; 165: 248–258.
3.
NagataYShozakiYNagahisaHNagasawaTAbeTTodokoroK. Serum thrombopoietin level is not regulated by transcription but by the total counts of both megakaryocytes and platelets during thrombocytopenia and thrombocytosis. Thromb Haemost1997; 77: 808–814.
4.
EmmonsRVReidDMCohenRL. Human thrombopoietin levels are high when thrombocytopenia is due to megakaryocyte deficiency and low when due to increased platelet destruction. Blood1996; 87: 4068–4071.
5.
SchedingSBergmannMShimosakaA. Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo. Transfusion2002; 42: 321–327.
KuterDJGernsheimerTB. Thrombopoietin and platelet production in chronic immune thrombocytopenia. Hematol Oncol Clin North Am2009; 23: 1193–1211.
8.
MukaiHYKojimaHTodokoroK. Serum thrombopoietin (TPO) levels in patients with amegakaryocytic thrombocytopenia are much higher than those with immune thrombocytopenic purpura. Thromb Haemost1996; 76: 675–678.
9.
MachlusKRItalianoJEJr. The incredible journey: From megakaryocyte development to platelet formation. J Cell Biol2013; 201: 785–796.
10.
Carver-MooreKBroxmeyerHELuohSM. Low levels of erythroid and myeloid progenitors in thrombopoietin-and c-mpl-deficient mice. Blood1996; 88: 803–808.
11.
ZiakasPDPapadakiHAPsyllakiMVoulgarelisM. Anti-thrombopoietin antibodies suppress megakaryocytic colony formation in vitro in patients with systemic lupus erythaematosus. Ann Rheum Dis2008; 67: 1643–1644.
12.
HepburnALNaratSMasonJC. The management of peripheral blood cytopenias in systemic lupus erythematosus. Rheumatology(Oxford)2010; 49: 2243–2254.
13.
BeyanEBeyanCTuranM. Hematological presentation in systemic lupus erythematosus and its relationship with disease activity. Hematology2007; 12: 257–261.
LippEvon FeltonASaxHMullerDBerchtoldP. Antibodies against platelet glycoproteins and antiphospholipid antibodies in autoimmune thrombocytopenia. Eur J Haematol1998; 60: 283–288.
16.
KrauseIBlankMFraserA. The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome. Immunobiology2005; 210: 749–754.
17.
ChenJHerceg-HarjacekLGroopmanJEGrabarekJ. Regulation of platelet activation in vitro by the c-Mpl ligand, thrombopoietin. Blood1995; 86: 4054–4062.
18.
KubotaYAraiTTanakaT. Thrombopoietin modulates platelet activation in vitro through protein-tyrosine phosphorylation. Stem Cells1996; 14: 439–444.
19.
BrizziMFBattagliaEMontrucchioG. Thrombopoietin stimulates endothelial cell motility and neoangiogenesis by a platelet-activating factor-dependent mechanism. Circ Res1999; 84: 785–796.
20.
KuterDJBusselJBNewlandA. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: Safety and efficacy. Br J Haematol2013; 161: 411–423.
21.
SeverinsenMTEngebjergMCFarkasDK. Risk of venous thromboembolism in patients with primary chronic immune thrombocytopenia: A Danish population-based cohort study. Br J Haematol2011; 152: 360–362.
22.
KaserABrandacherGSteurerW. Interleukin-6 stimulates thrombopoiesis through thrombopoietin: Role in inflammatory thrombocytosis. Blood2001; 98: 2720–2725.
23.
HollenCWHenthornJKoziolJABursteinSA. Elevated serum interleukin-6 levels in patients with reactive thrombocytosis. Br J Haematol1991; 79: 286–290.
24.
BrizziMFBattagliaERossoA. Regulation of polymorphonuclear cell activation by thrombopoietin. J Clin Invest1997; 99: 1576–1584.
25.
PetriM. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep2011; 13: 77–80.
26.
ReynaudQLegaJCMismettiP. Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: A systematic review and meta-analysis. Autoimmun Rev2014; 13: 595–608.
27.
ChungWSLinCLChangSNLuCCKaoCH. Systemic lupus erythematosus increases the risks of deep vein thrombosis and pulmonary embolism: A nationwide cohort study. J Thromb Haemost2014; 12: 452–458.
28.
TanEMCohenASFriesJF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
29.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
30.
EilertsenGOBecker-MerokANossentJC. The influence of the 1997 updated classification criteria for systemic lupus erythematosus: Epidemiology, disease presentation, and patient management. J Rheumatol2009; 36: 552–559.
31.
NikolaisenCFigenschauYNossentJC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. J Rheumatol2008; 35: 380–386.
32.
BobbaRSJohnsonSRDavisAM. A review of the sapporo and revised Sapporo criteria for the classification of antiphospholipid syndrome. Where do the revised sapporo criteria add value?J Rheumatol2007; 34: 1522–1527.
33.
Becker-MerokAEilertsenGONossentJC. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease. J Rheumatol2010; 37: 2039–2045.
34.
EilertsenGONikolaisenCBecker-MerokANossentJC. Interleukin-6 promotes arthritis and joint deformation in patients with systemic lupus erythematosus. Lupus2011; 20: 607–613.
35.
FurederWFirbasUNicholJL. Serum thrombopoietin levels and anti-thrombopoietin antibodies in systemic lupus erythematosus. Lupus2002; 11: 221–226.
36.
AbeYChoiIIkedaM. [Analyses of plasma thrombopoietin levels in patients with thrombocytopenia]. Rinsho Ketsueki2012; 53: 632–634.
37.
FukushimaTDongLSakaiT. Successful treatment of amegakaryocytic thrombocytopenia with anti—CD20 antibody (rituximab) in a patient with systemic lupus erythematosus. Lupus2008; 17: 210–214.
38.
KuwanaMKaburakiJOkazakiYMiyazakiHIkedaY. Two types of autoantibody—mediated thrombocytopenia in patients with systemic lupus erythematosus. Rheumatology(Oxford)2006; 45: 851–854.
39.
ZiakasPDRoutsiasJGGiannouliSTasidouATzioufasAGVoulgarelisM. Suspects in the tale of lupus—associated thrombocytopenia. Clin Exp Immunol2006; 145: 71–80.
40.
CeruttiACustodiPMdurantiCazzolaMBalduiniCL. Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant. Clin Lab Haematol1999; 21: 271–275.
41.
CeresaIFNorisPAmbaglioCPecciABalduiniCL. Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets2007; 18: 579–582.
42.
LupiaEBoscoOGoffiA. Thrombopoietin contributes to enhanced platelet activation in cigarette smokers. Atherosclerosis2010; 210: 314–319.
43.
BencivelliWVitaliCIsenbergDA. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerised clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol1992; 10: 549–554.
44.
LoodCErikssonSGullstrandB. Increased C1q, C4 and C3 deposition on platelets in patients with systemic lupus erythematosus – a possible link to venous thrombosis?Lupus2012; 21: 1423–1432.
45.
GewirtzAMZhangJRatajczakJ. Chemokine regulation of human megakaryocytopoiesis. Blood1995; 86: 2559–2567.
46.
MajkaMJanowska-WieczorekARatajczakJ. Numerous growth factors, cytokines, and chemokines are secreted by human CD34(+) cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner. Blood2001; 97: 3075–3085.
47.
SuehiroYMutaKUmemuraTAbeYNishimuraJNawataH. Macrophage inflammatory protein 1alpha enhances in a different manner adhesion of hematopoietic progenitor cells from bone marrow, cord blood, and mobilized peripheral blood. Exp Hematol1999; 27: 1637–1645.
48.
WhitcombBWSchistermanEFKlebanoffMABaumgartenMLuoXCheginiN. Circulating levels of cytokines during pregnancy: Thrombopoietin is elevated in miscarriage. Fertil Steril2008; 89: 1795–1802.
